/
Oncology
Advanced Solid Cancers
7
Pipeline Programs↗
4
Active Trials↗
6
Companies Involved↗
Advanced Solid Cancers is an early-stage landscape with 7 programs across 6 companies. The most active players are BioNTech, Shenzhen NewDEL Biotech, Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
7programs
Small molecule457%
Monoclonal antibody229%
Cell therapy114%
Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
19
clinical trials
Completed9 · 47%
Terminated5 · 26%
Recruiting2 · 11%
Enrolling by invitation1 · 5%
Unknown status1 · 5%
Active, not recruiting1 · 5%
Clinical Trials
Trial Activity
19 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)